Understanding the mechanisms of aromatase inhibitor resistance

William R Miller, Alexey A Larionov

Research output: Contribution to journalArticlepeer-review


ABSTRACT: Aromatase inhibitors (AIs) have a central role in the treatment of breast cancer; however, resistance is a major obstacle to optimal management. Evidence from endocrine, molecular and pathological measurements in clinical material taken before and after therapy with AIs and data from clinical trials in which AIs have been given as treatment either alone or in combination with other targeted agents suggest diverse causes for resistance. These include inherent tumour insensitivity to oestrogen, ineffective inhibition of aromatase, sources of oestrogenic hormones independent of aromatase, activation of signalling by non-endocrine pathways, enhanced cell survival and selection of hormone-insensitive cellular clones during treatment.
Original languageEnglish
Pages (from-to)201
JournalBreast Cancer Research
Issue number1
Publication statusPublished - 2012


Dive into the research topics of 'Understanding the mechanisms of aromatase inhibitor resistance'. Together they form a unique fingerprint.

Cite this